Clinical trials: Aggressive Behaviour
Dementia
Treating Behavioral Disturbances in Individuals With Dementia
This study will compare the safety and effectiveness two medications, citalopram (Celexa®) and risperidone (Risperdal®).
- Trial name
- NCT00073658
- Testing
- Citalopram, Risperidone
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- University of Pittsburgh
Cholestasis
Cholestasis in Extreme Low Birth Weight Infants (ELBW)
Parenteral nutrition associated liver disease (PNALD) in preterm neonates is characterized by early occurrence of intrahepatic cholestasis (parenteral nutrition associated cholestasis (PNAC).
- Trial name
- NCT01164878
- Volunteers
- 122 people
- Sponsor
- Medical University of Vienna
SCHIZOPHRENIA 1 (Disorder)
Effect of Fluvoxamine on Cognition, Behavior, Symptoms and mRNA and Protein Expression in Schizophrenia Patients
The purpose of this study is to determine effect of Fluvoxamine augmentation on cognitive function , aggressive behavior , clinical symptoms and mRNA (messenger ribonucleic acid) and protein expression in human peripheral…
- Trial name
- NCT01832285
- Testing
- fluvoxamine
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Sha'ar Menashe Mental Health Center
Generalized Aggressive Periodontitis
Metagenomic and Immune-inflammatory Analysis of Individuals With Generalized Aggressive Periodontitis and Their Descendants.
Generalized aggressive periodontitis (GAgP) is a multifactorial disease related to several aspects that influence its installation and progression.
- Trial name
- NCT03933514
- Testing
- Plaque control
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- University of Campinas, Brazil
Metabolic Syndrome
Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia
Schizophrenia patients treated with clozapine have a high prevalence of obesity-related metabolic syndrome. The condition is often poorly treated and may lead to the emergence of coronary heart disease and type 2 diabetes.
- Trial name
- ATOMICS (NCT00794963)
- Testing
- Pravastatin, Fenofibrate, Metformin, Orlistat, irbesartan, As selected by community physician
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Northwell Health
Lymphoma
A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00290706
- Testing
- bortezomib, gemcitabine hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Northwestern University
Problem Behavior, Aggression
Mind-Body Skills Groups for Behavioral and Emotional Problems in War-Traumatized Male Adolescents in Gaza
The purpose of this study is to determine whether war-traumatize male adolescents with behavioral and emotional problems who participate in mind-body skills groups will have improvement in behavioral and emotional problems…
- Conditions
- Problem Behavior, Aggression, Posttraumatic Stress Disorder
- Trial name
- NCT02671487
- Testing
- Mind-Body Skills Groups
- Where
- Palestinian Territories
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- The Center for Mind-Body Medicine
Desmoid Tumor, Aggressive Fibromatosis
Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
This study evaluates nirogacestat (PF-03084014) in the treatment of desmoid tumor/aggressive fibromatosis (DT/AF). In the double-blind phase, half of the participants will receive nirogacestat while the other half will receive…
- Trial name
- DeFi (NCT03785964)
- Testing
- Nirogacestat oral tablet
- Where
- 52 sites in United States, Belgium and 5 more
- Volunteers
- 142 people
- Sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Cyberbullying
Bullying Prevention Intervention for Adolescent Primary Care Patients
The purpose of this randomized controlled study is to evaluate acceptability and feasibility, and to gather preliminary data about efficacy, of "iPACT" (intervention to Prevent Adolescent Cyber-victimization with Text messages)…
- Trial name
- iPACT (NCT03467009)
- Testing
- iPACT Intervention, Control: Enhanced Usual Care (EUC), iPACT Intervention- app
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Rhode Island Hospital
B-cell Lymphoma
Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas
Multicenter prospective open-label non-randomised phase I/II study in patients with relapsed or refractory CD20-positive aggressive lymphomas Phase I: Dose escalation of methotrexate and cytarabine (days 1, 8 and 15 of each…
- Trial name
- LeMLAR (NCT01788189)
- Testing
- Lenalidomide
- Where
- Germany
- Volunteers
- 37 people
- Sponsor
- University Hospital, Essen
Lymphoma, Extranodal NK-T-Cell, EBV
Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma
To investigate the efficacy of autologous EBV-specific T-cells for the treatment of patients with aggressive EBV positive extranodal NK/T-cell lymphoma
- Trial name
- CITADEL (NCT01948180)
- Testing
- baltaleucel-T
- Where
- 11 sites in United States, France and 2 more
- Volunteers
- 15 people
- Sponsor
- Cell Medica Ltd
Offensive Aggression, Sexual Aggression
A Brief Intervention to Prevent Adolescent Dating Aggression Perpetration
The proposed study is a test of the feasibility and preliminary efficacy of a brief motivational interview style intervention. The intervention will take place in the pediatric emergency department of the Boston University…
- Conditions
- Offensive Aggression, Sexual Aggression, Dating Violence Perpetration and Victimization
- Trial name
- PLR (NCT02080923)
- Testing
- Brief Motivational Interview
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- Boston University
Refractory Leukemia, Relapsed Leukemia
Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias
The purpose of this research is to investigate whether the combination of STING-dependent Adjuvants (STAVs) and dendritic cell (DC) vaccine therapies will increase the body's ability to fight aggressive relapsed or refractory…
- Conditions
- Refractory Leukemia, Relapsed Leukemia, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- NCT05321940
- Testing
- STING-Dependent Activators (STAVs) Loaded Autologous Leukemic Cells, Dendritic Cell Vaccine
- Sponsor
- Juan C. Ramos, MD
Impulsive Aggression
Functional MRI Study in Healthy Children Engaged in Aggressive Behaviors
The purpose of this non-interventional study is to optimize the point subtraction aggression paradigms (PSAP) task in typically developing children (TDC).
- Trial name
- NCT03615703
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Supernus Pharmaceuticals, Inc.
B-cell Non-Hodgkins Lymphoma (B-NHL)
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
This study is researching an experimental drug called REGN5837 in combination with another drug, odronextamab (called "study drug[s]"), in patients with relapsed or refractory aggressive B-cell Non-Hodgkin Lymphomas (B-NHLs).
- Trial name
- ATHENA-1 (NCT05685173)
- Testing
- Odronextamab, REGN5837
- Where
- 20 sites in United States, France and 3 more
- Volunteers
- 107 people
- Sponsor
- Regeneron Pharmaceuticals
Lymphoma, Histiocytic Sarcoma
Pembrolizumab in Neoplasms or Lymphomas
This research study is studying a drug called pembrolizumab as a possible treatment for aggressive lymphoma or a histiocyte or dendritic cell neoplasm. The drug involved in this study is: -Pembrolizumab
- Conditions
- Lymphoma, Histiocytic Sarcoma, Follicular Dendritic Cell Sarcoma, Interdigitating Dendritic Cell Sarcoma
- Trial name
- NCT03316573
- Testing
- Pembrolizumab
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Dana-Farber Cancer Institute
Hematologic Malignancies
Repeat Dose Safety Study for Compound to Treat Hematologic Cancer
The purpose of this study is to characterize the safety and tolerability of repeat doses of compound GSK2110183 in subjects with hematologic cancer.
- Trial name
- NCT00881946
- Testing
- GSK21110183
- Where
- 4 sites in Australia, Canada and 1 more
- Volunteers
- 73 people
- Sponsor
- Accenture
Peripheral T-Cell Lymphoma
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
This study examines the use of denileukin diftitox (Ontak) for patients with peripheral T-cell lymphoma who are candidates for autologous stem cell transplants.
- Trial name
- NCT00632827
- Testing
- Gemcitabine, Navelbine, Doxorubicin Hydrochloride Liposome Injection
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of California, San Francisco
Aggressive B-Cell Lymphoma
G-Pola-GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma
The goal of this phase 2 trial is to test the safety and efficacy of G-Pola-GemOx as induction therapy in patients with Refractory/Relapsed Aggressive B-Cell Lymphoma.
- Trial name
- NCT07184788
- Testing
- Glofitamab, Polatuzumab Vedotin, Gemcitabine, and Oxaliplatin as Induction Therapy
- Volunteers
- 80 people
- Sponsor
- Navy General Hospital, Beijing
Acute Coronary Syndromes, Dyslipidemia
Early Triple Lipid-Lowering Therapy With Bempedoic Acid After Acute Coronary Syndrome
This randomized clinical trial will evaluate whether starting bempedoic acid in addition to high-intensity statin therapy and ezetimibe within 72 hours after percutaneous coronary intervention improves low-density lipoprotein…
- Trial name
- EARLY-BIRD ACS (NCT07824323)
- Testing
- bempedoic acid, Ezetimibe, High-Intensity Statin Therapy
- Where
- Taiwan
- Volunteers
- 400 people
- Sponsor
- Taipei Medical University Hospital